

Product Datasheet

TNG462

Catalog No. **BP-02049** · CAS **2760483-96-1** · Form **free base** · Physical state **other** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Histone Methyltransferase	Research area Cancer
--	--------------------------------

Molecular formula **C₂₈H₃₆N₆O₂S**

Molecular weight **520.6890**

STRUCTURE



DESCRIPTION

TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors.

BIOLOGICAL ACTIVITY

In Vitro

TNG-462 (0-1 μM) exhibits selectivity and inhibition of cell viability in MTAP deficient tumor cells (NSCLC, PDAC, bladder, hematological malignancies), with IC50 values less than 1 μM.

In Vivo

TNG-462 (40, 100 mg/kg; once daily (100 mg/kg) or b.i.d (40 mg/kg); 21 days; p.o.) has anti-tumor activity in a xenograft mouse model derived from MTAP deficient cell lines.

TNG-462 (30 mg/kg; twice daily; 5 weeks; p.o.) in combination with osimertinib (EGFR inhibitor) (HY-15772) (1 mg/kg; once daily; 5 weeks) has synergistic anti-tumor activity in MTAP-deficient cell line-derived xenograft mouse model.

SOLUBILITY

Soluble in DMSO

In vitro DMSO : 100 mg/mL

REFERENCES

- [1]. Briggs K, et al. TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors[J]. Cancer Research, 2023, 83(7_Supplement): 4970-4970.
- [2]. Kevin M Cottrell, et al. Piperidin-1-yl-n-pyridine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers. Patent WO2022026892A1.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.